Outcome of the Board Meeting held on Tuesday, November 11, 2025, i.e, today, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 8.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pharmaids Pharmaceuticals reported its Q2 FY26 (quarter ended Sep 30, 2025) results. Standalone revenue from operations surged to Rs. 596.55 lakhs in Q2 FY26 from Rs. 83.40 lakhs in Q2 FY25, while H1 FY26 revenue reached Rs. 708.08 lakhs vs Rs. 100.05 lakhs a year earlier. Despite the sharp revenue jump, the company posted a standalone loss after tax of Rs. 165.23 lakhs in Q2 (vs Rs. 100.66 lakh loss in Q2 FY25), cushioned by Rs. 313.05 lakhs of exceptional items (gain on sale of assets from exiting partnership firm Anugraha Chemicals). On a consolidated basis, Q2 revenue grew to Rs. 860.50 lakhs from Rs. 523.93 lakhs, but loss widened to Rs. 252.83 lakhs with Rs. 298.78 lakhs in exceptional items. Operating cash flow turned sharply negative at Rs. 372.63 lakhs in H1 FY26 vs a positive Rs. 37.12 lakhs in H1 FY25. Borrowings were substantially reduced (from Rs. 3,543 lakhs to Rs. 1,817 lakhs standalone) using proceeds from asset sales and the Anugraha exit.
Strong top-line growth is encouraging but persistent losses and negative operating cash flow signal the business is still in turnaround mode. The asset sale boosted near-term optics but underlying profitability remains weak, leaving shareholders with continued uncertainty over path to breakeven.